Literature DB >> 20133240

Acinar cell carcinoma of the pancreas in a young patient with chronic pancreatitis.

Fatima-Zahra Kebir1, Ahlem Lahmar, Nafaa Arfa, Saber Manai, Mohamed Ali El Ouaer, Saadia Bouraoui, Carole Gouttalier, Sabah Mezabi-Regaya.   

Abstract

BACKGROUND: Acinar cell carcinoma (ACC) is a rare malignancy of the pancreas arising from acinar cells. Unlike ductal adenocarcinoma, this tumor rarely presents with pancreatitis.
METHODS: We present a case of ACC associated with chronic calcifying pancreatitis, and a review of the literature focusing on diagnosis and management.
RESULTS: A 43-year-old man was proposed for Wirsungojejunal derivation for chronic pancreatitis. Histopathological examination of the tissue extracted revealed an ACC. Duodenopancreatectomy was performed. Six months post-operatively, the patient developed hepatic metastasis and was treated with gemcitabine as palliative chemotherapy.
CONCLUSIONS: The clinical presentation of ACC of the pancreas is not specific and the tumor can be under-diagnosed when associated with chronic pancreatitis. Data regarding course, treatment, and prognosis of this tumor are generally lacking.

Entities:  

Mesh:

Year:  2010        PMID: 20133240

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  3 in total

1.  Metachronous pancreatic acinar cell carcinoma discovered in early stage during follow-up of breast cancer: report of a case.

Authors:  Satoshi Hayama; Makoto Ohmi; Atsuya Yonemori; Takumi Yamabuki; Hitoshi Inomata; Kazuyoshi Nihei; Satoshi Hirano
Journal:  Clin J Gastroenterol       Date:  2012-07-21

2.  Spontaneous rupture of a pancreatic acinar cell carcinoma presenting as an acute abdomen.

Authors:  Afshin Mohammadi; Jalal Porghasem; Arefeh Esmaeili; Mohammad Ghasemi-Rad
Journal:  Int J Surg Case Rep       Date:  2012-03-30

3.  Clinical and CT imaging features of pancreatic acinar cell carcinoma.

Authors:  Shengping Hu; Shudong Hu; Mingliang Wang; Zhiyuan Wu; Fei Miao
Journal:  Radiol Med       Date:  2013-01-28       Impact factor: 3.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.